Adipose Tissues and Liver Changes Associated Semaglutide in CKD

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

November 15, 2027

Study Completion Date

January 15, 2028

Conditions

Chronic Kidney Disease in Type 2 Diabetes

Interventions

DRUG

Semaglutide (1 Mg Dose)

standard of care treatment

Trial Locations (1)

Mazankowski Alberta Heart Institute, Edmonton

All Listed Sponsors

collaborator

Novo Nordisk Canada Inc.

UNKNOWN

lead

University of Alberta

OTHER